Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo

Area of Science:

• Molecular biology
• Cell biology
• Cancer research

Background:

• Prostaglandin E2 (PGE2) is involved in tumorigenesis through G protein-coupled receptors (EP1-4).
• EP3 receptor is unique due to alternatively spliced variants (alpha, beta, gamma) with differing C-terminal tails.
• The functional role of EP3 variants in tumorigenesis remains unclear.

Purpose of the Study:

• To investigate the functional significance of murine EP3 receptor variants (alpha, beta, gamma) in regulating tumor cell potential.
• To elucidate the signaling pathway involved in EP3 variant-mediated suppression of tumorigenesis.

Main Methods:

• Expression of murine EP3 variants in tumor cells.
• In vivo tumorigenesis assays.
• In vitro cell proliferation and cell-cell contact assays.
• RhoA activation assays and G protein involvement studies.

Main Results:

• Expression of EP3 alpha, beta, and gamma variants significantly reduced tumor cell tumorigenic potential in vivo.
• Activation of all three mEP3 variants enhanced cell-cell contact and reduced cell proliferation in vitro.
• EP3-mediated effects were dependent on RhoA activation.
• RhoA activation by EP3 variants required the heterotrimeric G protein G(12).

Conclusions:

• Each of the three EP3 receptor variants suppresses tumor cell function.
• Suppression of tumor cell function is mediated by the activation of a G(12)-RhoA pathway.
• Selective activation of EP3 variants offers a potential therapeutic strategy for cancer treatment.